TRCT
GTBP icon

Tower Research Capital (TRC)’s GT Biopharma GTBP Stock Holding History

Tower Research Capital (TRC)’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$831 Sell
1,696
-2
-0.1% -$1 ﹤0.01% 4937
2026
Q1 		$693 Sell
1,698
-3
-0.2% -$2 ﹤0.01% 4798
2025
Q4 		$1.34K Sell
1,701
-3
-0.2% -$2 ﹤0.01% 4711
2025
Q3 		$999 Buy
1,704
+1,254
+279% +$1.87K ﹤0.01% 4895
2025
Q2 		$1.61K Sell
450
-468
-51% -$1.21K ﹤0.01% 4775
2025
Q1 		$1.97K Sell
918
-1,999
-69% -$4.7K ﹤0.01% 4613
2024
Q4 		$8.9K Buy
2,917
+1,274
+78% +$3.44K ﹤0.01% 3957
2024
Q3 		$3.79K Sell
1,643
-530
-24% -$1.27K ﹤0.01% 4773
2024
Q2 		$6.15K Sell
2,173
-128
-6% -$458 ﹤0.01% 4614
2024
Q1 		$10.2K Buy
2,301
+1,642
+249% +$8.67K ﹤0.01% 3732
2023
Q4 		$5.04K Sell
659
-13
-2% -$95 ﹤0.01% 4889
2023
Q3 		$4.86K Buy
672
+11
+2% +$91 ﹤0.01% 4805
2023
Q2 		$6.18K Sell
661
-286
-30% -$2.96K ﹤0.01% 4728
2023
Q1 		$16K Buy
947
+433
+84% +$9.92K ﹤0.01% 3696
2022
Q4 		$14K Buy
514
+335
+187% +$16.7K ﹤0.01% 3507
2022
Q3 		$9K Buy
179
+56
+46% +$4.28K ﹤0.01% 4654
2022
Q2 		$11K Buy
123
+15
+14% +$1.14K ﹤0.01% 4373
2022
Q1 		$9K Sell
108
-22
-17% -$1.94K ﹤0.01% 4453
2021
Q4 		$12K Buy
130
+16
+14% +$2.39K ﹤0.01% 4281
2021
Q3 		$23K Buy
114
+105
+1,167% +$31.6K ﹤0.01% 3592
2021
Q2 		$4K Sell
9
-36
-80% -$15K ﹤0.01% 4813
2021
Q1 		$9K Buy
+45
New +$7.86K ﹤0.01% 4422

Other funds holding GTBP

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
KP
Kitching Partners Conshohocken, Pennsylvania $116M AUM 16.12% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

Tower Research Capital (TRC)'s GTBP Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its GT Biopharma (GTBP) stake by 0.12% in Q2 2026, selling an estimated $1 and leaving 1,696 shares worth $831. The position accounts for ﹤0.01% of the portfolio, ranked #4937.

Tower Research Capital (TRC) first reported a position in GTBP in Q1 2021 and has held it in 22 quarters since. The position peaked at $23K in Q3 2021. 41 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Tower Research Capital (TRC) held 1,696 shares of GT Biopharma worth $831 as of Q2 2026.
  • Tower Research Capital (TRC) sold 2 GT Biopharma shares in Q2 2026, an estimated $1.
  • GT Biopharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4937 holding.
  • Tower Research Capital (TRC) first reported a position in GT Biopharma in Q1 2021 and has held it in 22 quarters since.
  • Tower Research Capital (TRC)'s GT Biopharma position peaked at $23K in Q3 2021.
  • 41 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.